Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atomo DiagnosticsASX:AT1 EV-to-OCF is -6.44 as of Aug. 07, 2026. The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Atomo Diagnostics ranks better than 74.53% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Atomo Diagnostics's Enterprise Value is A$14.14 Mil.
Atomo Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.20 Mil. Therefore, Atomo Diagnostics's EV-to-OCF for today is -6.44.
The historical rank and industry rank for Atomo Diagnostics's EV-to-OCF or its related term are showing as below:
ASX:AT1'
s EV-to-OCF Range Over the Past 10 Years
Min: -43.85 Med: -6.19 Max: 0.24
Current: -5.62
During the past 6 years, the highest EV-to-OCF of Atomo Diagnostics was 0.24. The lowest was -43.85. And the median was -6.19.
ASX:AT1's EV-to-OCF is ranked better than 74.53% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs ASX:AT1: -5.62
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atomo Diagnostics's PE Ratio (TTM) for today is calculated as:
Atomo Diagnostics's share price for today is A$0.019.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atomo Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atomo Diagnostics EV-to-OCF Related Terms
Atomo Diagnostics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Atomo Diagnostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's EV-to-OCF falls into.
Atomo Diagnostics's current Enterprise Value is A$14.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atomo Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a EV-to-OCF of -6.44 as of Aug. 07, 2026. According to the industry distribution chart, Atomo Diagnostics ranks #217 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Atomo Diagnostics' EV-to-OCF too high?
Atomo Diagnostics' current EV-to-OCF is -6.44. Based on the distribution chart, Atomo Diagnostics ranks #217 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Atomo Diagnostics' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #217 out of 852 companies for EV-to-OCF. This puts Atomo Diagnostics in the upper half of its industry. The industry median EV-to-OCF is 7.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current EV-to-OCF is -6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Fairly Valued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 5% below its estimated fair value. The current EV-to-OCF is -6.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current EV-to-OCF is -6.44 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 
